VERONA PHARMA P/S (NASDAQ:VRNA) – Analysts at SunTrust Banks increased their Q2 2019 earnings estimates for shares of VERONA PHARMA P/S in a research report issued to clients and investors on Tuesday, May 7th. SunTrust Banks analyst J. Lee now anticipates that the company will earn ($0.50) per share for the quarter, up from their previous forecast of ($0.89). SunTrust Banks also issued estimates for VERONA PHARMA P/S’s Q3 2019 earnings at ($0.58) EPS, Q4 2019 earnings at ($0.62) EPS, FY2019 earnings at ($2.24) EPS and FY2020 earnings at ($2.45) EPS.
Several other analysts have also recently weighed in on the company. Zacks Investment Research raised VERONA PHARMA P/S from a “hold” rating to a “buy” rating and set a $7.00 price objective for the company in a report on Tuesday, April 30th. BTIG Research assumed coverage on VERONA PHARMA P/S in a report on Wednesday, April 17th. They set a “buy” rating and a $17.00 price objective for the company. Finally, Wedbush reissued a “buy” rating on shares of VERONA PHARMA P/S in a report on Monday, January 14th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. VERONA PHARMA P/S currently has an average rating of “Buy” and a consensus price target of $26.50.
VERONA PHARMA P/S (NASDAQ:VRNA) last issued its quarterly earnings results on Tuesday, May 7th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.57) by $0.04.
An institutional investor recently raised its position in VERONA PHARMA P/S stock. Wedbush Securities Inc. boosted its position in shares of VERONA PHARMA P/S (NASDAQ:VRNA) by 75.5% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 24,800 shares of the company’s stock after purchasing an additional 10,670 shares during the quarter. Wedbush Securities Inc. owned about 0.19% of VERONA PHARMA P/S worth $161,000 as of its most recent filing with the Securities and Exchange Commission. 57.49% of the stock is currently owned by institutional investors and hedge funds.
VERONA PHARMA P/S Company Profile
Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and IIa clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease and cystic fibrosis.
Recommended Story: Should You Consider an Index Fund?
Receive News & Ratings for VERONA PHARMA P/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VERONA PHARMA P/S and related companies with MarketBeat.com's FREE daily email newsletter.